Lung Cancer
ASCO 2024: Osimertinib After Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
ASCO 2024: Osimertinib After Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
ESMO 2023: Pre- and Postsurgical Immunotherapy for Resectable Early-Stage NSCLC
Tobacco Cessation Treatment in Patients Eligible for Lung Cancer Screening
Factors Associated With Nonadherence to Lung Cancer Screening
ESMO 2022: Air Pollution and Non–Small Cell Lung Cancer Risk
Germline Testing for Patients With Lung Cancer: ASCO Plenary Series
NCCN Guidelines for Non–Small Cell Lung Cancer (Version 3.2022)
CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
Cancer During COVID-19: Resilience of Patients With Lung Cancer
T-DXd in Previously Treated Patients With Metastatic HER2-Mutant NSCLC